Biphenyl

Biphenyl

SCHEMBL4693704

O=C/C=C\c1ccccc1.c1ccc(-c2ccccc2)cc1

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.86
LMNA P02545 2/20 0.86
MAPK1 P28482 2/20 0.86
TRPA1 O75762 1/20 0.86
ALOX5 P09917 1/20 0.86
MAOB P27338 1/20 0.59
MAPT P10636 3/20 0.52
KDM4E B2RXH2 1/20 0.52
CDK4 P11802 3/20 0.50
CCND1 P24385 3/20 0.50
CCNB2 O95067 2/20 0.50
CDK1 P06493 2/20 0.50
CCNB1 P14635 2/20 0.50
CCNB3 Q8WWL7 2/20 0.50
CYP2A6 P11509 1/20 0.46
PLA2G7 Q13093 1/20 0.46
CMA1 P23946 1/20 0.45
HDAC2 Q92769 3/20 0.44
HDAC3 O15379 2/20 0.44
HDAC4 P56524 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL334479 0.93 ALDH1A1 (0.74) ALDH1A1LMNAMAPK1TRPA1ALOX5
SCHEMBL6016496 0.93 ALDH1A1 (0.74) ALDH1A1LMNAMAPK1TRPA1ALOX5
Cinnamaldehyde SCHEMBL28599267 0.93 ALDH1A1 (0.90) ALDH1A1LMNAMAPK1TRPA1ALOX5
Cinnamaldehyde SCHEMBL25267814 0.93 ALDH1A1 (1.00) ALDH1A1LMNAMAPK1TRPA1ALOX5
Cinnamic Aldehyde SCHEMBL159856 0.93 ALDH1A1 (1.00) ALDH1A1LMNAMAPK1TRPA1ALOX5
Cinnamaldehyde SCHEMBL28377500 0.93 ALDH1A1 (1.00) ALDH1A1LMNAMAPK1TRPA1ALOX5
Cinnamic Aldehyde SCHEMBL1866630 0.93 ALDH1A1 (1.00) ALDH1A1LMNAMAPK1TRPA1ALOX5
Cinnamaldehyde SCHEMBL2203965 0.93 ALDH1A1 (1.00) ALDH1A1LMNAMAPK1TRPA1ALOX5
Cinnamaldehyde SCHEMBL3442 0.93 ALDH1A1 (1.00) ALDH1A1LMNAMAPK1TRPA1ALOX5
Cinnamaldehyde SCHEMBL28377503 0.93 ALDH1A1 (1.00) ALDH1A1LMNAMAPK1TRPA1ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1284734-B1 ISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS CUREGENICS LTD (IL) 2008-05-21 EP disclosed
US-6949565-B2 Protein kinase inhibitors DEVELOGEN ISRAEL LTD. (IL) 2005-09-27 US disclosed
EP-1284734-A4 PROTEIN KINASE INHIBITORS PEPTOR LTD (IL) 2004-03-10 EP disclosed
US-20040019077-A1 Heterocyclic imines such as N1-(8-sulfonamide-5-isoquinoline)-N2-(3,3-diphenyl-2-propenyl) -ethylenediamine, used for prophylaxis and diagnosis of cancers, diabetes, cardiovascular and nervous system disorders, autoimmune diseases or obesity CUREGENICS LTD. (IL) 2004-01-29 US disclosed
EP-1284734-A1 PROTEIN KINASE INHIBITORS Peptor Ltd. (IL) 2003-02-26 EP disclosed
WO-2001091754-A1 PROTEIN KINASE INHIBITORS PEPTOR LTD. (IL) 2001-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019077-A1 Heterocyclic imines such as N1-(8-sulfonamide-5-isoquinoline)-N2-(3,3-diphenyl-2-propenyl) -ethylenediamine, used for prophylaxis and diagnosis of cancers, diabetes, cardiovascular and nervous system disorders, autoimmune diseases or obesity CHKB, MAP4K2, PKN2 ALDH1A1 3992/4885LMNA 1813/4885MAPK1 187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.